Dongsung Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Dongsung Pharmaceutical makes medicines and health-care products supplied to patients and the broader Korean health-care market.
The company is listed on KOSPI, South Korea's main stock exchange. The filing's table of contents covers pharmaceuticals as its core business, alongside research and development activities, but does not detail a single dominant product line beyond the general pharmaceutical scope.
Summary is AI-generated and may contain errors · figures from DART filings
Dongsung Pharmaceutical in five facts
What does Dongsung Pharmaceutical do?
Dongsung Pharmaceutical makes medicines and health-care products supplied to patients and the broader Korean health-care market.
Where is Dongsung Pharmaceutical listed and in which sector?
Dongsung Pharmaceutical (Korean name: 동성제약) trades under KRX code 002210 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Dongsung Pharmaceutical?
Its market capitalisation was US$95.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Dongsung Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Dongsung Pharmaceutical reported revenue of US$65.8M, an operating loss of US$7.6M and a net loss of US$19.4M, per its annual report on DART (data retrieved from DART on 2026-09-06). Revenue was down 1.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-06
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Court judgment/ruling on litigationSep 30
- Court judgment/ruling on litigationSep 14
- [Amended] Supply contract signed
Dongsung Pharmaceutical updated a previously disclosed supply contract with S&BD Korea Co., Ltd., now worth US$8.44M, about 13.4% of its recent annual revenue, running through May 2027.
Supply contract · Apr 22 - [Amended] Material event report (rights offering)
Dongsung Pharmaceutical updated the terms of convertible bonds to raise US$47.4M, about 56.4% of its market value.
Capital raise · Apr 22 · 3 versions - Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Apr 9
- [Amended] Material event report (convertible bonds)
Dongsung Pharmaceutical updated the terms of convertible bonds to raise US$33.1M, about 40.3% of its market value.
Capital raise · Apr 3 · 2 versions - Change of largest shareholderOwnership change · Mar 31
- Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Mar 31
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Dongsung Pharmaceutical reported separate results for FY2025: revenue of US$61.3M (−0.2% year on year), an operating loss of US$5.94M and a net loss of US$20.1M.
Earnings · Feb 19